Poland· PL-100474881
Pepaxti
A melphalan flufenamide product containing melphalani flufenamidum, registered in Poland by Oncopeptides AB (publ). The same ATC class is registered in 8 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Melphalan flufenamide is registered in 8 of 19 countries.
Countries holding a registration under ATC L01AA10 (melphalan flufenamide), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Melphalan flufenamide · ATC L01AA10
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Melphalani flufenamidum
- Manufacturer
- Oncopeptides AB (publ)
- Country
- Poland (PL)
- ATC code
- L01AA10
- ATC class
- Melphalan flufenamide
- Defined daily dose
- 1.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
10 interactions on record for melphalan flufenamide.
Graded by severity as the source publishes them — 4 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Melphalan flufenamide · interactions on record
10 records
- 4 moderate
- 6 minor
Most severe, free to view
- IfosfamideL01AA06moderate
- DacarbazineL01AX04moderate
- CytarabineL01BC01moderate
- VinblastineL01CA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Melphalan flufenamide in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumPepaxti 20 mgOncopeptides
- CzechiaPEPAXTIOncopeptides AB, Stockholm
- SpainPEPAXTI 20 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONOncopeptides Ab
- FinlandPepaxtiOncopeptides AB
- IrelandPepaxti 20 mg powder for concentrate for solution for infusionOncopeptides AB
- SwedenPepaxti 20 mg Pulver till koncentrat till infusionsvätska, lösningOncopeptides AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Pepaxti
- Liechtenstein · Pepaxti
- Norway · Pepaxti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/407c34a9-989b-4c47-b6ce-393f5822de27 GET /v1/drugs/407c34a9-989b-4c47-b6ce-393f5822de27?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "20 mg",
"packaging": "Rpz ¦ EU/1/22/1669/001 ¦ 147283\n1 fiol. 20 mg proszku",
"substance": "Melphalani flufenamidum 20 mg",
"common_name": "Melphalani flufenamidum",
"pl_product_id": "100474881",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about melphalan flufenamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.